AG
BBIO icon

Algert Global’s BridgeBio Pharma BBIO Stock Holding History

Algert Global’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Sell
205,497
-78,424
-28% -$5.49M 0.18% 151
2026
Q1 		$21.1M Sell
283,921
-57,127
-17% -$4.14M 0.32% 55
2025
Q4 		$26.1M Buy
341,048
+226,185
+197% +$14.8M 0.41% 25
2025
Q3 		$5.97M Buy
114,863
+50,110
+77% +$2.44M 0.1% 361
2025
Q2 		$2.8M Buy
+64,753
New +$2.36M 0.06% 526
2025
Q1 		– Sell
-23,600
Closed -$648K – 1183
2024
Q4 		$648K Sell
23,600
-112,847
-83% -$2.92M 0.02% 870
2024
Q3 		$3.47M Buy
136,447
+80,599
+144% +$2.12M 0.09% 372
2024
Q2 		$1.41M Sell
55,848
-33,558
-38% -$918K 0.05% 573
2024
Q1 		$2.76M Buy
89,406
+1,830
+2% +$62.2K 0.11% 311
2023
Q4 		$3.54M Buy
87,576
+22,012
+34% +$661K 0.14% 240
2023
Q3 		$1.73M Buy
65,564
+25,680
+64% +$729K 0.08% 412
2023
Q2 		$686K Sell
39,884
-2,430
-6% -$36.6K 0.03% 743
2023
Q1 		$702K Sell
42,314
-31,006
-42% -$362K 0.03% 746
2022
Q4 		$559K Buy
+73,320
New +$702K 0.03% 773
2022
Q3 		– Sell
-38,430
Closed -$349K – 1178
2022
Q2 		$349K Sell
38,430
-1,650
-4% -$13.8K 0.03% 876
2022
Q1 		$407K Buy
+40,080
New +$411K 0.03% 875

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Algert Global's BBIO Position: Q2 2026 in Review

Algert Global reduced its BridgeBio Pharma (BBIO) stake by 28% in Q2 2026, selling an estimated $5.49M and leaving 205,497 shares worth $15.3M. The position accounts for 0.18% of the portfolio, ranked #151.

Algert Global first reported a position in BBIO in Q1 2022 and has held it in 16 quarters since. The position peaked at $26.1M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Algert Global held 205,497 shares of BridgeBio Pharma worth $15.3M as of Q2 2026.
  • Algert Global sold 78,424 BridgeBio Pharma shares in Q2 2026, an estimated $5.49M.
  • BridgeBio Pharma made up 0.18% of Algert Global's portfolio in Q2 2026, its #151 holding.
  • Algert Global first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 16 quarters since.
  • Algert Global's BridgeBio Pharma position peaked at $26.1M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.